CLINICAL TRIALS PROFILE FOR OPTIRAY 240
✉ Email this page to a colleague
All Clinical Trials for OPTIRAY 240
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00793182 ↗ | Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography | Terminated | Guerbet | Phase 4 | 2009-01-01 | The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography. |
| NCT00793182 ↗ | Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography | Terminated | Mallinckrodt | Phase 4 | 2009-01-01 | The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography. |
| NCT03631771 ↗ | Pediatric Risk of Hypothyroidism With Iodinated Contrast Media | Not yet recruiting | Bayer | Phase 4 | 2022-03-01 | This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure. |
| NCT03631771 ↗ | Pediatric Risk of Hypothyroidism With Iodinated Contrast Media | Not yet recruiting | Duke Clinical Research Institute | Phase 4 | 2022-03-01 | This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure. |
| NCT03631771 ↗ | Pediatric Risk of Hypothyroidism With Iodinated Contrast Media | Not yet recruiting | Guerbet/Liebel-Flarsheim | Phase 4 | 2022-03-01 | This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure. |
| NCT03631771 ↗ | Pediatric Risk of Hypothyroidism With Iodinated Contrast Media | Not yet recruiting | GE Healthcare | Phase 4 | 2022-03-01 | This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure. |
| NCT04733092 ↗ | Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1) | Recruiting | Guerbet | Phase 1 | 2021-03-03 | Knee osteoarthritis is a common cause of disability in patients who are often young and active. Surgery being an option only for the most severe cases, there is little alternative in case of failure of recommended medication. Inflammatory hypervascularization of the joint is a known source of pain. Temporary embolization of intra-arterial inflammatory hypervascularization has been used since 2012 with good results on pain relief to treat patients with musculoskeletal disorders that are resistant to conventional treatments. Lipiodol® has transient embolizing properties when in emulsion with a contrast agent. It has been used as an emulsion with chemotherapy for the treatment of metastases and primary intra-arterial liver cancer (chemo-embolization) for many years without serious side effects. We hypothesized that Lipiodol® in emulsion could serve as a temporary embolization agent for the treatment of inflammatory hypervascularization responsible for musculoskeletal disorders in humans. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OPTIRAY 240
Condition Name
Clinical Trial Locations for OPTIRAY 240
Trials by Country
Clinical Trial Progress for OPTIRAY 240
Clinical Trial Phase
Clinical Trial Sponsors for OPTIRAY 240
Sponsor Name
